Rodrigues JC, et al. IgA nephropathy. Clin J Am Soc Nephrol 2017; 12:677–686. doi: 10.2215/CJN.07420716

• PubMed
Rodrigues JC, IgA nephropathy. Clin J Am Soc Nephrol 2017; 12:677–686. doi: 10.2215/CJN.07420716)| false
• Search Google Scholar
• Export Citation

Coppo R. Corticosteroids in IgA nephropathy: Lessons from recent studies. J Am Soc Nephrol 2017; 28:25–33. doi: 10.1681/ASN.2016060647

• PubMed
Coppo R. Corticosteroids in IgA nephropathy: Lessons from recent studies. J Am Soc Nephrol 2017; 28:25–33. doi: 10.1681/ASN.2016060647)| false
• Search Google Scholar
• Export Citation

Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines—application to the individual patient. Kidney Int 2012; 82:840–856. doi: 10.1038/ki.2012.280

• PubMed
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines—application to the individual patient. Kidney Int 2012; 82:840–856. doi: 10.1038/ki.2012.280)| false
• Search Google Scholar
• Export Citation

Pozzi C, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353:883–887. doi: 10.1016/s0140-6736(98)03563-6

• PubMed
Pozzi C, Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353:883–887. doi: 10.1016/s0140-6736(98)03563-6)| false
• Search Google Scholar
• Export Citation

Manno C, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24:3694–3701 [published correction appears in Nephrol Dial Transplant 2010; 25:1363−1364]. doi: 10.1093/ndt/gfp356

• PubMed
Manno C, Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24:3694–3701 [published correction appears in Nephrol Dial Transplant 2010; 25:1363−1364]. doi: 10.1093/ndt/gfp356)| false
• Search Google Scholar
• Export Citation

Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463

• PubMed
Rauen T, Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463)| false
• Search Google Scholar
• Export Citation

Barbour SJ, et al. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 2016; 89:167–175. doi: 10.1038/ki.2015.322

• PubMed
Barbour SJ, The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 2016; 89:167–175. doi: 10.1038/ki.2015.322)| false
• Search Google Scholar
• Export Citation

Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13:142–148. doi: 10.1681/ASN.V131142

• PubMed
Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13:142–148. doi: 10.1681/ASN.V131142)| false
• Search Google Scholar
• Export Citation

Vecchio M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2015; CD00396. doi: 10.1002/14651858.CD003965.pub2

• PubMed
Vecchio M, Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2015; CD00396. doi: 10.1002/14651858.CD003965.pub2)| false
• Search Google Scholar
• Export Citation

Lv J, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362

• PubMed
Lv J, Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362)| false
• Search Google Scholar
• Export Citation

Wheeler DC, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033

• PubMed
Wheeler DC, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033)| false
• Search Google Scholar
• Export Citation

Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab 2021; 33:732–739. doi: 10.1016/j.cmet.2021.02.016

• PubMed
Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab 2021; 33:732–739. doi: 10.1016/j.cmet.2021.02.016)| false
• Search Google Scholar
• Export Citation

Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 2013; 76:516–523. doi: 10.1111/bcp.12104

• PubMed
Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 2013; 76:516–523. doi: 10.1111/bcp.12104)| false
• Search Google Scholar
• Export Citation

Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int 2021; 100:24–26. doi: 10.1016/j.kint.2021.04.002

• PubMed
Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int 2021; 100:24–26. doi: 10.1016/j.kint.2021.04.002)| false
• Search Google Scholar
• Export Citation

Vasquez-Rios G, Nadkarni GN. SGLT2 inhibitors: Emerging roles in the protection against cardiovascular and kidney disease among diabetic patients. Int J Nephrol Renovasc Dis 2020; 13:281–296. doi: 10.2147/IJNRD.S268811

• PubMed
Vasquez-Rios G, Nadkarni GN. SGLT2 inhibitors: Emerging roles in the protection against cardiovascular and kidney disease among diabetic patients. Int J Nephrol Renovasc Dis 2020; 13:281–296. doi: 10.2147/IJNRD.S268811)| false
• Search Google Scholar
• Export Citation

Coppo R, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18:1880–1888. doi: 10.1681/ASN.2006040347

• PubMed
Coppo R, IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18:1880–1888. doi: 10.1681/ASN.2006040347)| false
• Search Google Scholar
• Export Citation

Li PK-T, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47:751–760. doi: 10.1053/j.ajkd.2006.01.017

• PubMed
Li PK-T, Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47:751–760. doi: 10.1053/j.ajkd.2006.01.017)| false
• Search Google Scholar
• Export Citation

Praga M, et al. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578–1583. doi: 10.1097/01.asn.0000068460.37369.dc

• PubMed
Praga M, Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578–1583. doi: 10.1097/01.asn.0000068460.37369.dc)| false
• Search Google Scholar
• Export Citation

Papeta N, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991–1996. doi: 10.1681/ASN.2011040434

• PubMed
Papeta N, APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991–1996. doi: 10.1681/ASN.2011040434)| false
• Search Google Scholar
• Export Citation

Sehic AM, et al. Increased recognition of IgA nephropathy in African-American children. Pediatr Nephrol 1997; 11:435–437. doi: 10.1007/s004670050311

• PubMed
Sehic AM, Increased recognition of IgA nephropathy in African-American children. Pediatr Nephrol 1997; 11:435–437. doi: 10.1007/s004670050311)| false
• Search Google Scholar
• Export Citation